Anergis discovers and develops proprietary, pharmaceutical-grade COP allergy vaccines for ultra-fast Allergy Immunotherapy based on its unique technology of Contiguous Overlapping Peptides (COP).

 

 

Contact

  • Biopôle III, Route de la Corniche 9B
    CH-1066 Epalinges
  • Email:
Top

This website uses cookies to ensure you get the best experience on our website.